samedan logo
 
 
 
spacer
home > ebr > autumn 2007 > anti-tumour agents: the next generation
PUBLICATIONS
European Biopharmaceutical Review

Anti-Tumour Agents: The Next Generation

Steve Dawber identifies current innovations and future developments in blood cancer targeted pharmacotherapy, in search of the significant prognostic improvements

Around 2.9 million cases of cancer are diagnosed in Europe each year. This extensive disease burden results in over 700,000 annual deaths – a mortality count that is expected to increase as the European population ages. Lymphomas and leukaemias, the two most common types of blood cancer, account for 200,000 of these cases, and are responsible for over 120,000 annual deaths. This is only 12,000 fewer than the deaths attributable to breast cancer (1).

Fortunately, however, the recent paradigm shift in our understanding of many underlying molecular cancer pathways and chemotherapeutic mechanisms has rapidly expanded the pharmacological approaches that are open to haematological oncologists. Gleevec (imatinib mesylate), for example, was specifically developed in order to prove that targeted therapy was a realisable concept and is now commonly used in the treatment of chronic myeloid leukaemia.

This article examines some of the current innovations in blood-cancer targeted pharmacotherapy, concentrating on the cancer types where treatment advances could culminate in the most significant prognostic improvements: diffuse large B-cell lymphoma; follicular lymphoma; lymphoblastic lymphoma; acute lymphoblastic leukaemia and chronic lymphocytic leukaemia. Whilst different approaches, such as radiotherapy, stem cell transplantation and immunotherapy, are also treatment options in this area, this article focuses on pharmacological approaches.

NON-HODGKIN’S LYMPHOMAS

The non-Hodgkin’s lymphomas (NHLs) comprise a heterogeneous collection of lymphoproliferative malignancies, which are most common in people aged over 55 years. While the incidence of most other cancers is decreasing, the incidence of NHL is on the rise. During the 1970s and 1980s, worldwide NHL incidence rose by three to four per cent per year. This rise has slowed in the 1990s, but an annual increase of one to two per cent is still being recorded (2). The two most common types of NHL are diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Steve Dawber, BSc (Hons), MCIJ, is an independent medical writer and journalist from Cheshire, UK. After graduating with a Pharmacology degree in 1992, Steve worked in UK pharmaceutical sales and marketing until August 2000. Steve has worked across a number of therapeutic areas during his seven years as a freelance writer and journalist, including asthma and allergy, cardiovascular disease, COPD, diabetes, erectile dysfunction, glaucoma, HIV, irritable bowel syndrome, neonatal infection, neuropathic pain, nuclear medicine, oncology, optical health, osteoporosis, transplantation and viraemia.
spacer
Steve Dawber
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

SONOTEC presents high accuracy flow meters for enhanced process quality and reproducibility at the Interphex show in New York

SONOTEC is back on the road again and presents its leading SONOFLOW® CO.55 clamp-on flow meters at the Interphex 2021 in New York. The highly accurate sensors are used in a wide range of applications, starting from process development to large-scale GMP production.
More info >>

White Papers

Device Develop for Combo Products

Phillips-Medisize

Combination products are defined as therapeutics combining two or more products (drug/device, biologics/device, biologics/drugs or drug/device/biologics), regulated and sold as a single unit. As these pharmaceutical and biological therapies and treatments have evolved, so has the need to develop appropriate delivery mechanisms for these applications. When developing a combination product, there are many things that need to be considered – the critical relationships between device development and the pharmaceutical or biologic, early establishment of regulatory and clinical strategies, understanding ‘user’ needs, determining product requirements, as well as, device manufacturing variation.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement